Nantahala Capital Management LLC bought a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,475,040 shares of the company’s stock, valued at approximately $20,038,646. Nantahala Capital Management LLC owned approximately 0.07% of Fulcrum Therapeutics as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of FULC. Quarry LP purchased a new stake in shares of Fulcrum Therapeutics in the 3rd quarter worth $35,000. Meeder Asset Management Inc. purchased a new position in shares of Fulcrum Therapeutics during the fourth quarter valued at $39,000. Summit Securities Group LLC purchased a new position in shares of Fulcrum Therapeutics during the first quarter valued at $53,000. The Manufacturers Life Insurance Company bought a new stake in shares of Fulcrum Therapeutics in the second quarter valued at about $61,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Fulcrum Therapeutics by 4,209.3% in the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after acquiring an additional 9,092 shares in the last quarter. 89.83% of the stock is owned by institutional investors.
Fulcrum Therapeutics Stock Performance
FULC opened at $3.85 on Friday. The firm has a market cap of $293.75 million, a price-to-earnings ratio of -3.18 and a beta of 3.05. Fulcrum Therapeutics, Inc. has a 12 month low of $2.83 and a 12 month high of $15.74. The stock has a fifty day moving average price of $3.73 and a 200-day moving average price of $6.00.
Wall Street Analysts Forecast Growth
FULC has been the topic of several recent research reports. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 target price on the stock. in a report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Friday, July 17th. Truist Financial cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a research report on Tuesday, June 2nd. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Finally, Citigroup lowered shares of Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a report on Tuesday, June 2nd. One research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $8.20.
Get Our Latest Analysis on FULC
Insider Buying and Selling
In other Fulcrum Therapeutics news, Director Alan Ezekowitz sold 18,000 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $3.65, for a total transaction of $65,700.00. Following the completion of the sale, the director directly owned 10,927 shares of the company’s stock, valued at approximately $39,883.55. This represents a 62.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.30% of the company’s stock.
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.
Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.
Read More
- Five stocks we like better than Fulcrum Therapeutics
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding FULC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report).
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
